Se ha curado de VIH por células madre.

Realmente impresionante.

/summon Mv-biologists

Me resulta extraño que de ser cierta la noticia,no se hayan hecho eco los medios más importantes y esté publicada en todos los periódicos,estamos hablando de,si no la peor,una de las peores infecciones del mundo y nunca a habido método alguno para curar al 100% dicha infección :/

#9 yo no, gente muy querida por mi si.

#5 muy fácil:

1º lo que tu pienses no significa que sea verdad.
2º Si fuese verdad, investigar no es mirar, ver que 2+2 son 4 y sacar la vacuna. Es mucho más difícil.
3º Estudia medicina y se un eminente científico y descúbrelo tú. (Sí, no lo harás)

Puede ser posible pero vamos que este tipo tuvo muchísima suerte ya que 1º ha sobrevivido a una leucima y su tratamiento 2º que el donante tuviera linfocitos ccr5- 3º que la cepa con la que estaba infectado fuese hacia el correcptor ccr5 ya que hay otras que actuan a traves del correcptor CXCR4

Existe un fármaco llamado Maraviroc que bloquea CCR5

Que genial la noticia, y que alegría se habrá llevado el hombre! : )

Joder este caso es viejísimo, de hecho al leer el título estaba pensando exactamente en el mismo.

noticion, esperemos que algun dia se consiga, aunque seguramente al desaparecer el sida apareceran 700 enfermedades nuevas mas.

un avance increíble

soy el unico que piensa que cuando se cure el sida y el cancer, aparecera el soda y el concer?

Es curioso como la industria farmaceutica siempre termina sobreviviendo gracias a la aparicion de nuevas enfermedades y/o cepas resistentes que requieren de mas y mas medicacion.

Que alguien ponga la foto del tio con el gorrito de papel de plata, gracias.

Joooder, ya era hora, por fín

Ahora vendrán todos los ultracatólicos y demás religiosos extremistas a decir que hacer eso es una aberración con la obra del señor.

#25 Ya, cojonuda esa escena xD "Why we are not finance this?"

Ehhh, ¡¡¡pero investigar con células madre es inmoral!!

Si es como lo pintan esta noticia debería de ser portada de todos los periódicos y telediarios a escala mundial.

Para los interesados y metidos en el tema:

The case history

The 'Berlin patient' is an HIV-positive man who developed acute myeloid leukaemia, received successful treatment and subsequently experienced a relapse in 2007 that required a transplant of stem cells.

Doctors chose stem cells from an individual who had an unusual genetic profile: a mutation inherited from both parents that resulted in CD4 cells that lacked the CCR5 receptor. This mutation, called CCR5 delta 32 homozygosity, is present in less than 1% of Caucasians in northern and western Europe, and is associated with a reduced risk of becoming infected with HIV.

This is because all new infecting viruses need to use the CCR5 receptor on CD4 cells when infecting an immune system cell of the CD4 type.

Later in the course of HIV infection another type of virus emerges that can use the CXCR4 receptor instead.

Before the stem cell transplant the patient received chemotherapy treatment that destroyed most immune cells and total body irradiation, and also received immunosuppressive drugs to prevent rejection of the stem cells.

Antiretroviral therapy was halted on the day of the transplant, and the patient had to receive a second stem cell transplant 13 days after the first one, due to a further relapse of leukaemia.

The patient continued to receive immunosuppressive treatment to prevent rejection for 38 months, and at 5, 24 and 29 months post-transplant colon biopsies were taken to investigate possible graft-versus-host disease in the intestine. At each investigation additional samples were taken to check for signs of HIV infection in the abundant immune cells of the gut wall.

During the 38 month follow-up period the donor CD4 cells repopulated the mucosal immune system of the gut, to such an extent that the frequency of CD4 cells was almost twice as high as in HIV-negative healthy controls, and this phenomenon was also seen in a control group of ten HIV-negative individuals who received stem cell transfers.

The repopulation of CD4 cells was accompanied by the complete disappearance of host CD4 cells, and after two years the patient had the CD4 count of a healthy adult of the same age.

One of the challenges for any approach to curing HIV infection is long-lived immune system cells, which need to be cleared before a patient can be cured. In the case of the Berlin patient CCR5-bearing macrophages could not be detected after 38 months, suggesting that chemotherapy had destroyed these longer-lived cells, and that they had also been replaced by donor cells.

The German researchers and San Francisco-based immunologist Professor Jay Levy believe that the findings point to the importance of suppressing the production of CCR5-bearing cells, either through transplants or gene therapy.

The patient did not resume antiretroviral therapy after the transplant.

Nevertheless HIV remained undetectable by both viral load testing (RNA) and tests for viral DNA within cells, and HIV antibody levels declined to the point that the patient has no antibody reactivity to HIV core antibodies, and only very low levels of antibodies to the HIV envelope proteins.

Seventeen months after the transplant the patient developed a neurological condition, which required a brain biopsy and lumbar puncture to sample the cerebrospinal fluid for diagnostic purposes. HIV was also undetectable in the brain and the CSF.

An additional indication that HIV is not present lies in the fact that the patient’s CD4 cells are vulnerable to infection with virus that targets the CXCR4 receptor. If any virus with this preference was still present, the researchers argue, it would be able to swiftly infect the large population of memory CD4 cells that has emerged